Treatment of insomnia

Primary Psychiatry

Volumn 12, Issue 8, 2005, Pages 47-56

  Infante, Mauricio ^a   Benca, Ruth ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE RECEPTOR; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; CLONAZEPAM; DIPHENHYDRAMINE; DOXEPIN; ESTAZOLAM; ESZOPICLONE; FLURAZEPAM; GABAPENTIN; HYPNOTIC AGENT; MELATONIN; MIRTAZAPINE; NEUROLEPTIC AGENT; NON PRESCRIPTION DRUG; OLANZAPINE; QUAZEPAM; QUETIAPINE; RAMELTEON; RISPERIDONE; TEMAZEPAM; TIAGABINE; TRAZODONE; TRIAZOLAM; UNCLASSIFIED DRUG; VALERIAN; ZALEPLON; ZOLPIDEM;

AMNESIA; ATAXIA; BEHAVIOR DISORDER; BEHAVIOR THERAPY; CHILD PSYCHIATRY; COGNITIVE THERAPY; COMORBIDITY; CONSTIPATION; DIZZINESS; DROWSINESS; DRUG HALF LIFE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DYSKINESIA; FALLING; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HUMAN; HYPOKINESIA; INCIDENCE; INCREASED APPETITE; INSOMNIA; MENTAL PATIENT; MYALGIA; ORTHOSTATIC HYPOTENSION; PATIENT SELECTION; PRIAPISM; PSYCHOPHYSIOLOGY; PSYCHOTHERAPY; RELAXATION TRAINING; REM SLEEP; RESTLESS LEGS SYNDROME; REVIEW; SECONDARY INSOMNIA; SHORT COURSE THERAPY; SLOW WAVE SLEEP; SLURRED SPEECH; TASTE DISORDER; URINE RETENTION; VISUAL IMPAIRMENT; WEIGHT GAIN; XEROSTOMIA;

EID: 23844523173     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (102)

1. Buysse DJ, Reynolds CF 3rd, Hauri PJ, et al. Diagnostic concordance for DSM-IV sleep disorders: a report from the APA/NIMH DSM-IV field trial. Am J Psychiatry. 1994;151(9):1351-1360.
2. Asnis GM, Chakraburtty A, DuBoff EA, et al. Zolpidem for persistent insomnia in SSRI-treated depressed patients. J Clin Psychiatry. 1999;60(10):668-676.
3. Wehr TA. Sleep loss: a preventable cause of mania and other excited states. J Clin Psychiatry. 1989;50(Suppl):8-16;45-17.
4. Foley DJ, Monjan A, Simonsick EM, Wallace RB, Blazer DG, Incidence and remission of insomnia among elderly adults: an epidemiologic study of 6,800 persons over three years. Sleep. 1999;22(Suppl 2):S366-S372.
5. Chesson AL, Jr., Andersen WM, Littner M, et al. Practice parameters for the nonpharmacologic treatment of chronic insomnia. An American Academy of Sleep Medicine report. Standards of Practice Committee of the American Academy of Sleep Medicine. Sleep. 1999;22(8):1128-1133.
6. McClusky HY, Milby JB, Switzer PK, Williams V, Woolen V. Efficacy of behavioral versus triazolam treatment in persistent sleep-onset insomnia. Am J Psychiatry. 1991;148(1):121-126.
7. Hauri PJ. Can we mix behavioral therapy with hypnotics when treating insomniacs? Sleep. 1997;20(12):1111-1118.
8. Morin CM, Hauri PJ, Espie CA, Spielman AJ, Buysse DJ, Bootzin RR. Nonpharmacologic treatment of chronic insomnia. An American Academy of Sleep Medicine review. Sleep. 1999;22(8):1134-1156.
9. Morin C, Culbert J, Schwartz S. Nonpharmacological interventions for insomnia: a meta-analysis of treatment efficacy. Am J Psychiatry. 1994;15:1172-1180.
10. Murtagh DR, Greenwood KM. Identifying effective psychological treatments for insomnia: a meta-analysis. J Consult Clin Psychol. 1995;63(1):79-89.
11. Smith MT, Perlis ML, Park A, et al. Comparative meta-analysis of pharmacotherapy and behavior therapy for persistent insomnia. Am J Psychiatry. 2002;159(1):5-11.
12. Edinger JD, Means MK. Cognitive-behavioral therapy for primary insomnia. Clin Psychol Rev. 2005;25(5):539-558.
13. Smith MT, Huang MI, Manber R. Cognitive behavior therapy for chronic insomnia occurring within the context of medical and psychiatric disorders. Clin Psychol Rev. 2005;25(5):559-592.
14. Bonnet MH, Arand DL. The consequences of a week of insomnia. Sleep. 1996;19(6):453-461.
15. Edinger JD, Sampson WS. A primary care "friendly" cognitive behavioral insomnia therapy. Sleep. 2003;26(2):177-182.
16. Manber R, Bootzin RR, Acebo C, Carskadon MA. The effects of regularizing sleep-wake schedules on daytime sleepiness. Sleep. 1996;19(5):432-441.
17. Spielman AJ, Saskin P, Thorpy MJ. Treatment of chronic insomnia by restriction of time in bed. Sleep. 1987;10(1):45-56.
18. Morin CM, Colecchi C, Stone J, Sood R, Brink D. Behavioral and pharmacological therapies for late-life insomnia: a randomized controlled trial. JAMA. 1999;281(11):991-999.
19. Espie CA, Lindsay WR, Brooks DN, Hood EM, Turvey T. A controlled comparative investigation of psychological treatments for chronic sleep-onset insomnia. Behav Res Ther. 1989;27(1):79-88.
20. Ladouceur R, Gros-Louis Y. Paradoxical intention vs stimulus control in the treatment of severe insomnia. J Behav Ther Exp Psychiatry. 1986;17(4):267-269.
21. Turner RM, Ascher LM. Controlled comparison of progressive relaxation, stimulus control, and paradoxical intention therapies for insomnia. J Consult Clin Psychol. 1979;47(3):500-508.
22. Turner RM, Ascher LM. Therapist factor in the treatment of insomnia. Behav Res Ther. 1982;20(1):33-40.
23. Lacks P, Bertelson A, Gans L, Kunkel J. The effectiveness of three behavioral treatments for different degrees of sleep-onset insomnia. Behav Ther. 1983;14:593-605.
24. Nishino S, Mishima K, Mignot E, Dement W. Sedative-Hypnotics. In: AF S, Nemeroff CB, eds. Textbook of Psychopharmacology. Arlington, VA: American Psychiatric Publishing, Inc.; 2004:651-670.
25. Scharf MB, Roth PB, Dominguez RA, Ware JC. Estazolam and flurazepam: a multicenter, placebo-controlled comparative study in outpatients with insomnia. J Clin Pharmacol. 1990;30(5):461-467.
26. Melo de Paula AJ. Comparative study of lormetazepam and flurazepam in the treatment of insomnia. Clin Ther. 1984;6(4):500-508.
27. Hernandez Lara R, Del Rosal PL, Ponce MC. Short-term study of quazepam 15 milligrams in the treatment of insomnia. J Int Med Res. 1983;11(3):162-166.
28. Cohn JB, Wilcox CS, Bremner J, Ettinger M. Hypnotic efficacy of estazolam compared with flurazepam in outpatients with insomnia. J Clin Pharmacol. 1991;31(8):747-750.
29. Aden G, Thatcher C. Quazepam in the shortterm treament of insomnia in outpatients. J Clin. Psychiatry. 1983;44(12):454-456.
30. Holbrook AM, Crowther R, Lotter A, Cheng C, King D. Meta-analysis of benzodiazepine use in the treatment of insomnia. CMAJ. 2000;162(2):225-233.
31. Kales A, Manfredi RL, Vgontzas AN, Bixler EO, Vela-Bueno A, Fee EC. Rebound insomnia after only brief and intermittent use of rapidly eliminated benzodiazepines. Clin Pharmacol Ther. 1991;49(4):468-476.
32. Roehrs T, Vogel G, Vogel F, et al. Dose effects of temazepam tablets on sleep. Drugs Exp Clin Res. 1986;12(8):693-699.
33. Mitler MM, Carskadon MA, Phillips RL, et al. Hypnotic efficacy of temazepam: A longterm sleep laboratory evaluation. Br J Clin Pharmacol. 1979;8:63S-68S.
34. Ngen CC, Hassan R. A double-blind placebo-controlled trial of zopiclone 7.5 mg and temazepam 20 mg in insomnia. Int Clin Psychopharmacol. 1990;5(3):165-171.
35. Mitler MM, Seidel WF, van den Hoed J, Greenblatt DJ, Dement WC. Comparative hypnotic effects of flurazepam, triazolam, and placebo: a long-term simultaneous nighttime and daytime study. J Clin Psychopharmacol. 1984;4(1):2-13.
36. Dolly FR, Block AJ. Effect of flurazepam on sleep-disordered breathing and nocturnal oxygen desaturation in asymptomatic subjects. Am J Med. 1982;73(2):239-243.
37. Mahowald MW, Schenck CH. REM Sleep Parasomnias. In: Kryger MH, Roth T, Dement W, eds. Principles and Practice of Sleep Medicine. IV ed. Philadelphia, PA: Elsevier Saunders; 2005:897-916.
38. Ware JC, Walsh JK, Scharf MB, Roehrs T, Roth T, Vogel GW. Minimal rebound insomnia after treatment with 10-mg zolpidem. Clin Neuropharmacol. 1997;20(2):116-125.
39. Dockhorn RJ, Dockhorn DW. Zolpidem in the treatment of short-term insomnia: a randomized, double-blind, placebo-controlled clinical trial. Clin Neuropharmacol. 1996;19(4):333-340.
40. Roth T, Roehrs T, Vogel G. Zolpidem in the treatment of transient insomnia: a double-blind, randomized comparison with placebo. Sleep. 1995;18(4):246-251.
41. Scharf MB, Roth T, Vogel GW, Walsh JK. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry. 1994;55(5):192-199.
42. Walsh J, Erman M, Erwin C. Subjective hypnotic efficacy of trazodone and zolpidem in DSM-III-R primary insomnia. Human Psychopharmacology. 1998;13:191-198.
43. Walsh JK, Roth T, Randazzo A, et al. Eight weeks of non-nightly use of zolpidem for primary insomnia. Sleep. 2000;23(8):1087-1096.
44. Saletu-Zyhlarz G, Anderer P, Brandstatter N, et al. Placebo-controlled sleep laboratory studies on the acute effects of zolpidem on objective and subjective sleep and awakening quality in nonorganic insomnia related to neurotic and stress-related disorder. Neuropsychobiol. 2000;41(3):139-148.
45. Shaw SH, Curson H, Coquelin JP. A doubleblind, comparative study of zolpidem and placebo in the treatment of insomnia in elderly psychiatric in-patients. J Int Med Res. 1992;20(2):150-161.
46. Wang PS, Bohn RL, Glynn RJ, Mogun H, Avorn J. Zolpidem use and hip fractures in older people. J Am Geriatr Soc. 2001;49(12):1685-1690.
47. Mendelson WB. Clinical distinctions between long-acting and short-acting benzodiazepines. J Clin Psychiatry. 1992;53 Suppl:4-7;8-9.
48. Brassington GS, King AC, Bliwise DL. Sleep problems as a risk factor for falls in a sample of community-dwelling adults aged 64-99 years. J Am Geriatr Soc. 2000;48(10):1234-1240.
49. Elie R, Ruther E, Fair I, Emilien G, Salinas E. Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. Zaleplon Clinical Study Group. J Clin Psychiatry. 1999;60(8):536-544.
50. Fry J, Scharf M, Mangano R, Fujimori M. Zaleplon improves sleep without producing rebound effects in outpatients with insomnia. Zaleplon Clinical Study Group. Int Clin Psychopharmacol. 2000;15(3):141-152.
51. Verster JC, Volkerts ER, Schreuder AH, et al. Residual effects of middle-of-the-night administration of zaleplon and zolpidem on driving ability, memory functions, and psychomotor performance. J Clin Psychopharmacol. 2002;22(6):576-583.
52. Hedner J, Yaeche R, Emilien G, Farr I, Salinas E. Zaleplon shortens subjective sleep latency and improves subjective sleep quality in elderly patients with insomnia. The Zaleplon Clinical Investigator Study Group. Int J Geriatr Psychiatry. 2000;15(8):704-712.
53. Walsh JK, Vogel GW, Scharf M, et al. A five week, polysomnographic assessment of zaleplon 10 mg for the treatment of primary insomnia. Sleep Med. 2000;1(1):41-49.
54. Leese P, Maier G. Eszopiclone: pharmacokinetic and pharmacodynamic effects of a novel anti-insomnia agent after daytime administration in healthy patients. Sleep Abstract Suppl. 2002;25:A45.
55. Krystal AD, Walsh JK, Laska E, et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, doubleblind, placebo-controlled study in adults with chronic insomnia. Sleep. 2003;26(7):793-799.
56. Zammit G, Gillin JC, McNabb L, Caron J, Roth T. Eszopiclone, a novel nonebenzodiazepine. Sleep Abstract Suppl. 2003;26:A297.
57. Wilson S, Argyropoulos S. Antidepressants and sleep: a qualitative review of the literature. Drugs. 2005;65(7):927-947.
58. Katz DA, McHorney CA. The relationship between insomnia and health-related quality of life in patients with chronic illness. J Fam Pract. 2002;51(3):229-235.
59. Hajak G, Rodenbeck A, Voderholzer U, et al. Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study. J Clin Psychiatry. 2001;62(6):453-463.
60. Rush CR, Baker RW, Wright K. Acute behavioral effects and abuse potential of trazodone, zolpidem and triazolam in humans. Psychopharmacology (Berl). 1999;144(3):220-233.
61. Parrino L, Spaggiari MC, Boselli M, Di Giovanni G, Terzano MG. Clinical and polysomnographic effects of trazodone CR in chronic insomnia associated with dysthymia. Psychopharmacology. 1994;116(4):389-395.
62. Scharf MB, Sachais BA. Sleep laboratory evaluation of the effects and efficacy of trazodone in depressed insomniac patients. J Clin Psychiatry. 1990;51 Suppl:13-17.
63. Montgomery I, Oswald I, Morgan K, Adam K. Trazodone enhances sleep in subjective qualitv but not in objective duration. Br J Clin Pharmacol. 1983;16(2):139-144.
64. Saletu-Zyhlarz GM, Abu-Bakr MH, Anderer P, et al. Insomnia in depression: differences in objective and subjective sleep and awakening quality to normal controls and acute effects of trazodone. Pŕog Neuropsychopharmacol Biol Psychiatry. 2002;26(2):249-260.
65. Nowell PD, Reynolds CF, 3rd, Buysse DJ, Dew MA, Kupfer DJ. Paroxetine in the treatment of primary insomnia: preliminary clinical and electroencephalogram sleep data. J Clin Psychiatry. 1999;60(2):89-95.
66. Winokur A, DeMartinis NA, 3rd, McNally DP, Gary EM, Cormier JL, Gary KA. Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia. J Clin Psychiatry. 2003;64(10):1224-1229.
67. Winokur A, Sateia MJ, Hayes JB, Bayles-Dazet W, MacDonald MM, Gary KA. Acute effects of mirtazapine on sleep continuity and sleep architecture in depressed patients: a pilot study. Biol Psychiatry. 2000;48(1):75-78.
68. Silvestri R, Pace-Schott EF, Gersh T, Stickgold R, Salzman C, Hobson JA. Effects of fluvoxamine and paroxetine on sleep structure in normal subjects: a home-based Nightcap evaluation during drug administration and withdrawal. J Clin Psychiatry. 2001;62(8):642-652.
69. Sharpley AL, Vassallo CM, Cowen PJ. Olanzapine increases slow-wave sleep: evidence for blockade of central 5-HT(2C) receptors in vivo. Biol Psychiatry. 2000;47(5):468-470.
70. Salin-Pascual RJ, Herrera-Estrella M, Galicia-Polo L, Laurrabaquio MR. Olanzapine acute administration in schizophrenic patients increases delta sleep and sleep efficiency. Biol Psychiatry. 1999;46(1):141-143.
71. Herrmann N, Lanctot KL. Do atypical antipsychotics cause stroke? CNS Drugs. 2005;19(2):91-103.
72. Rosack J. FDA orders new warning on atypical antipsychotics. Psychiatric News. May 2005;40(9).
73. Ketter TA, Post RM, Theodore WH. Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. Neurology. 1999;53(5 Suppl 2):S53-S67.
74. Foldvary-Schaefer N. Sleep complaints and epilepsy: the role of seizures, antiepileptic drugs and sleep disorders. J Clin Neurophysiol. 2002;19(6):514-521.
75. Mathias S, Wetter TC, Steiger A, Lancel M. The GABA uptake inhibitor tiagabine promotes slow wave sleep in normal elderly subjects. Neurobiol Aging. 2001;22(2):247-253.
76. Rickels K, Morris RJ, Newman H, Rosenfeld H, Schiller H, Weinstock R. Diphenhydramine in insomniac family practice patients: a double-blind study. J Clin Pharmacol. 1983;23(5-6):234-242.
77. Richardson GS, Roehrs TA, Rosenthal L, Koshorek G, Roth T. Tolerance to daytime sedative effects of H1 antihistamines. J Clin Psychopharmacol. 2002;22(5):511-515.
78. Witek TJ, Jr., Canestrari DA, Miller RD, Yang JY, Riker DK. Characterization of daytime sleepiness and psychomotor performance following H1 receptor antagonists. Ann Allergy Asthma Immunol. 1995;74(5):419-426.
79. Dubocovich ML. Melatonin receptors: are there multiple subtypes? Trends Pharmacol Sci. 1995;16(2):50-56.
80. Haimov I, Lavie P, Laudon M, Herer P, Vigder C, Zisapel N. Melatonin replacement therapy of elderly insomniacs. Sleep. 1995;18(7):598-603.
81. Hughes RJ, Sack RL, Lewy AJ. The role of melatonin and circadian phase in age-related sleep- maintenance insomnia: assessment in a clinical trial of melatonin replacement. Sleep. 1998;21(1):52-68.
82. Ellis CM, Lemmens G, Parkes JD. Melatonin and insomnia. J Sleep Res. 1996;5(1):61-65.
83. Wagner J, Wagner ML, Hening WA. Beyond benzodiazepines: alternative pharmacologic agents for the treatment of insomnia. Ann Pharmacother. 1998;32(6):680-691.
84. Walsh JK, Rosenberg R, Roth T. Treatment of primary insomnia for five weeks with Indiplon-IR. Sleep Abstract Suppl. 2004;27:A259.
85. Jochelson P, Scharf M, Roth T. Efficacy of Indiplon in inducing and maintaining sleep in patients with chronic sleep maintenance insomnia. Sleep Abstract Suppl. 2004:A262.
86. Owens JA, Spirito A, McGuinn M, Mobile C. Sleep habits and sleep disturbance in elementary school-aged children. J Dev Behav Pediatr. 2000;21(1):27-36.
87. Lozoff B, Wolf AW, Davis NS. Sleep problems seen in pediatric practice. Pediatrics. 1985;75(3):477-483.
88. Blader JC, Koplewicz HS, Abikoff H, Foley C. Sleep problems of elementary school children. A community survey. Arch Pediatr Adolesc Med. 1997;151(5):473-480.
89. Morrison DN, McGee R, Stanton WR. Sleep problems in adolescence. J Am Acad Child Adolesc Psychiatry. 1992;31(1):94-99.
90. Ferber R. Sleeplessness in the child. In: Kryger MH, Roth T, Dement W, eds. Principles and Practice of Sleep Medicine. I ed. Philadelphia, PA: WB Saunders; 1989:633-639.
91. Mindell JA. Empirically supported treatments in pediatric psychology: bedtime refusal and night wakings in young children. J Pediatr Psychol 1999;24(6):465-481.
92. Glaze DG. Childhood insomnia: why Chris can't sleep. Pediatr Clin North Am. 2004;51(1):33-50.
93. Owens JA, Palermo TM, CL R. Overview of current management of sleep disturbances in children. II: Behavioral interventions. Curr Ther Res Clin Exp. 2002;63(Suppl B):B38-B52.
94. Reid KJ, Zee PC. Circadian disorders of the sleep-wake cycle. In: Kryger MH, Roth T, Dement W, eds. Principles and Practice of Sleep Medicine. IV ed. Philadelphia, PA: Elsevier Saunders; 2005:691-701.
95. Pelayo R, Chen W, Monzon S, Guilleminault C. Pediatric sleep pharmacology: you want to give my kid sleeping pills? Pediatr Clin North Am. 2004;51(1):117-134.
96. Reed M, Findling R. Overview of current management of sleep disturbances in children. I: Pharmacotherapy. Curr Ther Res Clin Exp. 2002;63(Suppl B):B18-B37.
97. Thomas L, King R. Child and adolescent psychiatric emergencies. In: Lewis M, ed. Child and Adolescent Psychiatry A Comprehensive Textbook. Philadelphia, PA: Lippincott Williams & Wilkins; 2002:1104-1110.
98. Greydanus DE, Sloane MA, Rappley MD. Psychopharmacology of ADHD in adolescents. Adolesc Med. 2002;13(3):599-624.
99. Phillips L, Appleton RE. Systematic review of melatonin treatment in children with neurodevelopmental disabilities and sleep impairment. Dev Med Child Neurol. 2004;46(11):771-775.
100. Smits MG, van Stel HF, van der Heijden K, Meijer AM, Coenen AM, Kerkhof GA, Melatonin improves health status and sleep in children with idiopathic chronic sleeponset insomnia: a randomized placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2003;42(11):1286-1293.
101. Werry JS, Dowrick PW, Lampen EL, Vamos MJ. Imipramine in enuresis-psychological and physiological effects. J Child Psychol Psychiatry. 1975;16(4):289-299.
102. Rapoport JL, Mikkelsen EJ, Zavadil A, et al. Childhood enuresis. II. Psychopathology, tricyclic concentration in plasma, and antienuretic effect. Arch Gen Psychiatry. 1980;37(10):1146-1152.